A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2024-12-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of AZD4604 when administered as single or multiple inhaled doses to healthy Japanese and Chinese participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

NCT00687232

Healthy

COMPLETED PHASE1

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects

NCT01096563

Healthy

TERMINATED PHASE1

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

NCT06951880

Healthy Participants

NOT_YET_RECRUITING PHASE1

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379

Healthy Participants

COMPLETED PHASE1

Single and Multiple Ascending Doses of AZD1981 in Japan

NCT00698282

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will comprise of two parts: Part 1 and Part 2

Part 1 will investigate the safety, tolerability, and PK of inhaled AZD4604 following single ascending and multiple doses in healthy Japanese participants.

Part 1a will include three single ascending dose (SAD) cohorts and Part 1b will include one multiple dose cohort.

Part 2 will investigate the safety, tolerability, and PK of inhaled AZD4604 following single ascending and multiple doses in healthy Chinese participants.

Part 2a will include two SAD cohort and Part 2b will include one multiple dose cohort.

Part 1a and Part 2a will comprise of:

1. A Screening Visit within 28 days before dosing.
2. A treatment period (Day 1 to Day 7)
3. A final assessment on Day 7

Part 1b and Part 2b will comprise of:

1. A Screening Visit within 28 days before dosing.
2. A treatment period (Day 1 to Day 13)
3. A final assessment on Day 13

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1a: AZD4604 (Dose 1) SAD

Japanese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 1a: AZD4604 (Dose 2) SAD

Japanese participants will receive single dose of AZD4604 (Dose 2) via inhalation on Day 1.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 1a: AZD4604 (Dose 3) SAD

Japanese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 1a: Placebo

Japanese participants will receive single dose of matching placebo to AZD4604 on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered as DPI.

Part 1b: AZD4604 (Dose 4) Multiple dose cohort

Japanese participants will receive AZD4604 (Dose 4) via inhalation twice daily (BID) from Day 1 to Day 6 and a single dose on Day 7.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 1b: Placebo

Japanese participants will receive matching placebo to AZD4604 BID from day 1 to day 6 and a single dose of placebo on Day 7.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered as DPI.

Part 2a: AZD4604 (Dose 1) SAD

Chinese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 2a: AZD4604 (Dose 3) SAD

Chinese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 2a: Placebo

Chinese participants will receive single dose of matching placebo to AZD4604 on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered as DPI.

Part 2 b: AZD4604 (Dose 4) Multiple dose cohort

Chinese participants will receive AZD4604 (Dose 4) via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Part 2b: Placebo

Chinese participants will receive placebo via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered as DPI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD4604

AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention Type DRUG

Placebo

Placebo will be administered as DPI.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Japanese participants who are born in Japan, has 2 Japanese biological parents, 4 Japanese grandparents as confirmed by the interview and has lived outside Japan for less than 10 years at the time of screening.
* Chinese participants who are born in China, has 2 Chinese biological parents, 4 Chinese grandparents as confirmed by the interview and has lived outside China for less than 10 years at the time of screening.
* Have body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 45 kg.
* Healthy participants must have a Forced Expiratory Volume at first breath (FEV1) ≥ 80% of the predicted value in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria at the Screening and admission visits.
* Female participants must have a negative pregnancy test.

Exclusion Criteria

* History or presence of clinically important disease which may put participant at risk because of participation in study.
* Participant has an increased risk of infection.
* History of malignancy other than superficial basal cell carcinoma, having a first degree relative with lung cancer or disease history suggesting abnormal immune function.
* Has received any vaccine 30 days prior to first dose.
* Has a body temperature of \> 37.7°C on Day -1.
* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
* Known or suspected history of drug abuse, alcohol abuse or excessive intake of alcohol.
* Current smokers or those who have smoked or used nicotine products (including e-cigarettes, vaping, and nicotine replacement therapy) within the previous 6 months or has a smoking history of \> 5 pack-years.
* History of a serious or severe adverse reaction to AZD4604 or any of its additive constituents.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604.
* Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss\> 500 mL during the 3 months prior to the Screening Visit.
* Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead safety ECG.
* Female participants who are planning a pregnancy during the study period or within 1 month after the last dose of study intervention.
* Abnormal vital signs at the Screening Visit, after 5 minutes supine rest.
* History of any significant respiratory disorders such as asthma (a history of childhood asthma without symptoms or treatment after the age of 10 years is allowable), chronic obstructive pulmonary disease, or idiopathic pulmonary fibrosis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes